Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reimbursement Is More Than Passing Thought For Spine Firm In FDA Trials

This article was originally published in The Gray Sheet

Executive Summary

Non-fusion spinal implant maker Paradigm Spine decided to spend 15%-20% more than needed to satisfy FDA's data requirements in an ongoing pivotal trial for what the company hopes will be its first product on the U.S. market

You may also be interested in...



FDA And CMS Agree To Share Data Routinely In Step Toward Parallel Reviews

Routine sharing of data between FDA and CMS will be possible for the first time under a June 23 memorandum of understanding that could serve as a first step toward parallel reviews for marketing approval and Medicare coverage

FDA And CMS Agree To Share Data Routinely In Step Toward Parallel Reviews

Routine sharing of data between FDA and CMS will be possible for the first time under a June 23 memorandum of understanding that could serve as a first step toward parallel reviews for marketing approval and Medicare coverage

Expectations For Artificial Disc Trials Challenge Market Hopefuls

Completing a pivotal trial may be the biggest challenge developers of artificial discs face as the market for the devices gets more crowded, say consultants

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT025844

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel